A recent study with mirabegron 50 mg and 25 mg in Chinese participants with overactive bladder (OAB) has been completed. The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of OAB in Chinese participants. Additionally, the study evaluated the safety of mirabegron for the treatment of OAB, assessed other efficacy variables, and explored different mirabegron starting doses. The study was sponsored by Astellas Pharma China, Inc. and involved 249 participants in China.
---
Source: ClinicalTrials.gov
調査・レポート2026年8月23日•1分で読めます
Mirabegron Study for OAB Completed
3
1
Astellas Pharma's mirabegron study for overactive bladder in China is completed. The study evaluated efficacy and safety of mirabegron.
PharmaCountryチームがまとめました · 出典： ClinicalTrials.gov
評価
(0)
(0)
(0)
(0)
(0)
評価を残す